NexImmune, Inc. (NEXI)
| Market Cap | 139.00 -50.2% |
| Revenue (ttm) | n/a |
| Net Income | -20.62M |
| EPS | -17.39 |
| Shares Out | 1.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171 |
| Open | 0.0001 |
| Previous Close | n/a |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 2.1700 |
| Beta | 4.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, a... [Read more]
Financial Performance
Financial StatementsNews
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
Neximmune announces $3.67M registered direct offering priced at-the-market
NexImmune announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares…
Neximmune terminates equity sales agreement and ATM program
In a regulatory filing, NexImmune stated that as previously disclosed in June 2022, the company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald and BTIG, pursuant to…
Neximmune Inc trading halted, volatility trading pause
14:00 EST Neximmune Inc trading halted, volatility trading pause
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
Neximmune Inc trading halted, volatility trading pause
09:36 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
09:52 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
12:04 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
09:37 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
09:34 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
09:32 EST Neximmune Inc trading halted, volatility trading pause
Neximmune Inc trading halted, volatility trading pause
09:33 EST Neximmune Inc trading halted, volatility trading pause
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping
Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by mo...
Neximmune, Yale, JDRF extend research partnership with Type 1 diabetes
NexImmune announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, depl...
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune...
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...